Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 4;21:66. doi: 10.1186/s12943-022-01541-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022, corrected publication 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — Gilteritinib upregulated the expression of NKG2DLs and FLT3 in AML cells from patients with FLT3^mut+ and FLT3^mut− AML and in the bone marrow of xenograft mouse models. A-B Flow cytometry analysis indicated that NKG2DL expression in AML cells from patients with FLT3^mut+ or FLT3^mut− AML was significantly elevated with gilteritinib treatment. Histograms show NKG2DL expression on FLT3^mut+ or FLT3^mut− AML in the absence (grey) and presence (black) of gilteritinib for 24 h. Inset numbers showed the ratio in MFI of treated/non-treated cells. C The upregulation of FLT3 following gilteritinib treatment was only detected in cells from patients with FLT3^mut+ AML and not in cells from patients with FLT3^mut− AML. Histograms show FLT3 expression on FLT3^mut+ or FLT3^mut− AML in the absence (grey) and presence (black) of gilteritinib for 24 h. Inset numbers showed the ratio in MFI of treated/non-treated cells. D In xenograft models, bone marrow immunofluorescence staining showed the density of NKG2DL ULBP1 and FLT3 cells. E The diagram showed the MFIs of NKG2DL ULBP1 (green) and FLT3 (red) measured by ImageJ from n = 3 mice in each group. G, gilteritinib; MFI, mean fluorescence intensity. ns, not significant. * p < 0.05; ** p < 0.01; *** p < 0.001